Shopping Cart
There are no more items in your cart
News
ABT has been awarded the "Innovative SME" label by the Spanish Ministry of Science, Innovation and Universities
This seal confirms the company's commitment to research, custom development and innovation in the field of bioprocessing.
Read more
Next stop: The industry's top trade shows
Agarose Bead Technologies (ABT) is excited to announce our participation in several important trade fairs this October.
Read more
Agarose Bead Technologies expands facility to meet rising global demand for novel therapies market
Agarose Bead Technologies has enhanced its Burgos facility by boosting its agarose resin production to 100,000 liters annually to position itself as a powerhouse in the novel therapies market.
Read moreSee you at Bioprocess International Conference and Exhibition 2024
ABT will be exhibiting at one of the most prestigious events in the bioprocessing industry, the Bioprocess International Conference. This prestigious event will be held...
Read more"The use of agarose bead resins — such as those offered by ABT — makes the difference by providing gentle and scalable conditions essential for obtaining intact, functional proteins in critical antiviral development studies"
A recent study evaluated screening strategies to identify inhibitors of the SARS-CoV-2 RdRp complex, the enzyme responsible for viral replication.
Using both fluorometric and electrophoretic assays, the researchers revealed that fluorescence-based methods (with SYBR Green) can yield false positives due to compound interference with fluorophore binding—an effect intensified in the presence of 6 mM MgCl₂. Although several compounds appeared to inhibit RdRp in the fluorometric assay, only suramin, corilagin, and simeprevir showed marked inhibition in independent electrophoretic tests.
The study used a SARS-CoV-2 RdRp complex purified via affinity chromatography with nickel-coupled agarose bead resins, ensuring the isolation of high-quality, functional proteins. This purification step was essential for accurate enzymatic activity assessment and for eliminating misleading readouts caused by fluorometric interference.
Figure 1. Schematic of the purification procedure of the nsp12-nsp8-nsp7 complex and electrophoresis separation of the purified RdRp complex.
The findings also show that while suramin is the most potent inhibitor, it affects multiple nucleic acid-binding enzymes, suggesting its action is not specific to SARS-CoV-2 RdRp. This underscores the importance of biochemically validating virtual screening results to identify true antiviral candidates. In this regard, the study is crucial for discovering new antiviral compounds, paving the way toward more precise and effective therapies against COVID-19 and potentially other viral infections.
In summary, the success of identifying and validating effective inhibitors relies not only on compound selection but also on the robustness of enzyme purification processes. The use of agarose bead resins — such as those offered by ABT — makes the difference by providing gentle and scalable conditions essential for obtaining intact, functional proteins in critical antiviral development studies.
Agarose Bead Technologies (ABT) positions itself as a strategic partner in these workflows. Our agarose resins — such as Nickel NTA Rapid Run — efficiently purify His-tag proteins, maintaining their stability and delivering consistently high performance under diverse conditions and pressures, from laboratory to industrial scale.
- Susana Llanos, Bruno Di Geronimo, Ester Casajús, Elena Blanco-Romero, Rafael Fernández-Leiro & Juan Méndez. Interference of small compounds and Mg2+ with dsRNA-binding fluorophores compromises the identification of SARS-CoV-2 RdRp inhibitors. Nature Scientific Reports (2024) 14:28250